Please login to the form below

Not currently logged in
Email:
Password:

Latest NICE drug recommendations

The National Institute for Health and Clinical Excellence (NICE) has today published final guidance on drugs for hepatitis B and leukaemia

NICE is recommending the use of tenofovir disoproxil for the treatment of people in whom antiviral treatment is indicated with chronic HBeAg-positive or HBeAg-negative hepatitis B.

This guidance does not apply to people with chronic hepatitis B who also have hepatitis C, hepatitis D or HIV.

Dr Gillian Leng, NICE deputy chief executive, said: "Hepatitis B can have a serious impact on a person's quality of life, and those with the disease are more likely to develop serious liver problems such as cirrhosis and cancer. This guidance means that patients with the virus will have another treatment option available to combat the problem of viral resistance to other drug therapies."

NICE has also published guidance on the use of rituximab for the first line treatment of chronic lymphocytic leukaemia, recommending rituximab as a possible first treatment for people with chronic lymphocytic leukaemia who are able to take fludarabine in combination with cyclophosphamide.

Rituximab should only be used in combination with fludarabine and cyclophosphamide, and is not recommended in combination with any other chemotherapy agents as a first-line treatment for chronic lymphocytic leukaemia.

Dr Carole Longson, NICE health technology evaluation centre director, said: "After looking at all of the available evidence, the independent Appraisal Committee concluded that rituximab, when used as a first line treatment for people with chronic lymphocytic leukaemia who are able to take fludarabine in combination with cyclophosphamide, represented an effective use of NHS resources. This important guidance increases the treatment options available to people with this condition, wherever they live in England and Wales."

22nd July 2009

From: Healthcare

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....
AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...
Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....

Infographics